Pocket Guide: Biologics in Upper and Lower Airways in Adults

The introduction of biologics for the treatment of severe upper and lower (type 2) airway inflammation has been a game changer in the management of these diseases. Biologics are injectable medications targeting different molecules relevant in (type 2) inflammation in patients with severe (type 2) airway diseases, like asthma, eosinophilic chronic obstructive pulmonary disease (COPD), chronic rhinosinusitis (CRS) and those who remain uncontrolled despite regular treatment. After the phase 3 trials, showing significant impact on symptoms, quality of life and interventions like surgery (for the upper airways) and exacerbations needing hospitalisation (for the lower airways), biologics are now used in daily practice in many parts of the world.

This pocket guide is aimed at all specialists treating adult patients with severe airway disease. Click here to access the pocket guide on the EUFOREA website!

Co-Authors: Wytske Fokkens, Vibeke Backer, Valerie Lund, Peter Barnes, Manuel Bernal-Sprekelsen, Leif Bjermer, Eugenio de Corso, Diego Conti, Marjolein Cornet, Zuzana Diamant, Ratko Djukanovic, Mina Gaga, Philippe Gevaert, Joseph Han, Claire Hopkins, Guy Joos, Basile Landis, Susanne Lau, Stella Lee, Joachim Mullol, Anju Peters, Glenis Scadding, Sven Schneider, Brent Senior, Ian Pavord, Santiago Quirce, Dermot Ryan, Michael Wechsler, Peter Hellings